Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity

Part of paid clinical trials in St Louis, Missouri.

Sponsor
Washington University School of Medicine
Study ID
NCT07091500
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Exercise training — BEHAVIORAL
    Participants will perform supervised exercise training sessions 3 days per week and unsupervised at-home sessions 2-3 days per week.
  • Semaglutide — DRUG
    semaglutide 2.4 mg subcutaneous per week or max tolerated dose and diet behavior counseling

Study Details

The use of glucagon-like peptide receptor agonists (GLP-1 RAs) may have clinically important effects on skeletal muscle mass (SMM), and physical function. The effects of exercise training in conjunction with GLP-1 RA therapy on these outcomes has not been studied. Additionally, most people treated with GLP-1-based weight loss medications stop taking these medications within 1 year of initiating treatment. This is an important clinical concern because weight regain can occur after weight loss pharmacotherapy is stopped and the impact of stopping GLP-1 RA therapy on physical and metabolic function has not been studied. In this study, the investigators will conduct a 2-year randomized clinical trial to evaluate body composition, muscle physical and metabolic function, and muscle strength in response to GLP-1 RA therapy, with or without exercise training, and subsequent treatment cessation on muscle-related outcomes.

Key Dates

Start date
Aug 11, 2025
Status verified
Sep 2025
Primary completion
Aug 1, 2028
Completion
Aug 1, 2029

Study Design

Enrollment
40 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Active Comparator: GLP-1 RA
    Participants in this group will receive semaglutide therapy along with diet behavior counseling for 52 weeks
  • Experimental: GLP-1 RA + Exercise
    Participants in this group will receive semaglutide therapy along with diet behavior counseling and exercise training for 52 weeks.

Primary Outcome Measure

Physical function [ Time Frame: Baseline, after 52 weeks of intervention, and 52 weeks after stopping the intervention ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Washington University School of MedicineSt LouisMissouri63110
Coordinator
314-273-1879

Find similar trials in St Louis, MO

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Washington University School of Medicine· St Louis, MO

Related Studies